Takeda Bumps Forecast On 'Significant Momentum' Pre-Shire
Takeda raises full-year forecast after "significant momentum" in the first half, driven by mainstays, cost savings and delayed US generic competition to Velcade.
You may also be interested in...
As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.
Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.
Approved in late August, the HAE prophylaxis drug has already yielded $51m in US revenues, with EU approval expected by year-end. The HAE franchise is a growth leader for Shire, despite peaks and valleys due to supply issues.